Inverness unloads nutritionals
This article was originally published in The Tan Sheet
The maker of consumer diagnostic devices sells its legacy nutritionals business for $63.4 million in cash to International Vitamin Corporation, Inverness Medical Innovations announces Jan. 19. Inverness Medical Nutritionals generated net revenues of $63.6 million and an operating loss of $2.4 million in the first nine months of 2009, the Waltham, Mass., company said. The unit's supplement products include Stresstabs vitamins, Posture-D calcium supplements and Ferro-Sequels iron supplements. Inverness moved into smoking-cessation and other therapeutic services with its $100 million acquisition of Free & Clear Inc. (1"The Tan Sheet" Nov. 2, 2009)
You may also be interested in...
Medical diagnostic firm Inverness Medical Innovations seeks shareholder approval to rechristen itself Alere - the name of its health management services business. The change announced May 18 reflects the firm's continuing evolution toward integrated health management and therapeutic services and away from legacy operations, such as the nutritionals business it divested in January (1"The Tan Sheet" Jan. 25, 2010, In Brief). Inverness, based in Waltham, Mass., also announced first-quarter net revenue of $515.3 million, a 21.2 percent gain. Revenue from the consumer diagnostics unit fell 24 percent to $24.7 million in the January-March period, Inverness said April 28. However, product revenues from the company's joint venture with Procter & Gamble rose 15 percent to $55.9 million. Inverness' quarterly net income jumped 118.5 percent to $14.2 million
Launches underlie Reckitt consumer growth: Recent line extensions, including Nurofen Express pain reliever and Strepsils Cool throat lozenges, enable Reckitt Benckiser's Health & Personal Care business to grow 16 percent to $869.5 million (533 million U.K. pounds under Oct. 27 conversion rates) during the fiscal 2009 third quarter. "Those products are doing extremely well and clearly underpin the growth rate that we are seeing" in the segment, CEO Bart Becht said Oct. 27. In a same-day release, the U.K. firm cited Dettol hygiene products, Gaviscon antacid and Mucinex cough/cold remedy as major growth drivers. Becht told analysts to expect additional launches in February 2010. Reckitt reported overall net revenue of $3.1 billion in the July-September period, a 7 percent gain. Quarterly net income was $582.4 million, up 12 percent
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.